Table 1.
ApoE genotype and allele frequencies for patients with AD, bvFTD, and healthy controls
| Subjects | ApoE genotype |
Allele frequency, % |
ε4 carriers, % | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| ε2/ε2 | ε2/ε3 | ε2/ε4 | ε3/ε3 | ε3/ε4 | ε4/ε4 | ε2 | ε3 | ε4 | ||
| AD (51 subjects) | 0 | 1* | 0 | 20* | 26** | 4** | 1.0* | 65.7 | 33.3** | 58.8 |
| bvFTD (31 subjects) | 0 | 3 | 0 | 20 | 8 | 0 | 4.8 | 82.3 | 12.9 | 25.8 |
| Controls (56 subjects) | 1 | 10 | 2 | 35 | 8 | 0 | 12.5 | 78.6 | 8.9 | 17.9 |
Differences among the groups in apoE genotypes and allele frequencies were tested by using the Pearson χ2 test.
*Significantly lower than controls (P < 0.05).
**Significantly higher than controls (P < 0.05).